New research indicates that individuals who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover lost weight much more quickly than those who end traditional diet and exercise regimens.
Published data in a leading health publication shows that while obese people can lose about a fifth of their body weight while on the medication, the weight is regained at an average rate of 0.8 kg per month after stopping.
"People purchasing these medications must be cognizant of the danger of rapid weight regain when the medication concludes," cautioned lead investigator Dr. Susan Jebb.
Such speed of recovery means a reversion to starting mass within about a year and a half.
Comparing Therapies
The analysis, which reviewed dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Researchers point out that individuals who lose weight through dieting typically see a more gradual weight regain—around 0.1 kg a month—after stopping.
Understanding the Quick Regain
Nutrition scientists suggest the mode of action of the drugs accounts for the amplified weight return.
These medications mimic a body's own chemical called GLP-1, which moderates appetite.
"Sustained high doses of the hormone levels far above than normal could lead to the body to generate a reduced amount of its own natural GLP-1, and may also reduce sensitivity to its actions," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this hormone supplement means hunger is no longer kept in check, making excessive eating much more probable."
A Chronic Issue?
The NHS suggest the jabs for people with weight-linked medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, given the likelihood of weight regain, the treatment might need to be life-long.
This opinion is echoed by pharmaceutical companies, who say that the findings "underscore the long-term nature of obesity," akin to managing diseases like diabetes.
User Testimonies
Users who have come off the medication report a intense resurgence of appetite.
"It felt as if a trigger activating and you become extremely hungry," recalled an individual.
The struggle is worsened if individuals have not adopted sustainable dietary or behavioural changes during treatment.
Widespread Use
Figures indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with interest being substantial.
- Adoption is more common among females than men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Finally, clinicians caution that while these medications are potent agents for weight loss, they are not a permanent cure and maintained weight loss relies on integrated behavioural support.
